Approaching Proof of Concept for Antigen Specific Immunotherapy in Type 1 Diabetes – Precision Therapy in HLA DR3-DQ2 Patients

• Updates from the ongoing DIAGNODE-3 phase 3 trial, (interim readout expected March, 2026)
• Review of pharmacodynamic effects of rhGAD65 treatment
• Evidence of disease-modifying benefit in Stage 3 Type 1 diabetes and strategy to guide next-phase development and future precision-medicine strategies

Speakers:

Anton Lindqvist

Chief Scientific Officer

Diamyd Medical